We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $67.50, marking a +0.42% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.22%. Meanwhile, the Dow gained 0.7%, and the Nasdaq, a tech-heavy index, added 0.08%.
Prior to today's trading, shares of the heart monitoring device maker had gained 28.48% over the past month. This has outpaced the Medical sector's gain of 7.58% and the S&P 500's gain of 9.27% in that time.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. This is expected to be February 28, 2019. On that day, BEAT is projected to report earnings of $0.42 per share, which would represent year-over-year growth of 31.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $103.02 million, up 12.29% from the year-ago period.
Investors might also notice recent changes to analyst estimates for BEAT. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BEAT is currently a Zacks Rank #1 (Strong Buy).
Digging into valuation, BEAT currently has a Forward P/E ratio of 37.76. For comparison, its industry has an average Forward P/E of 20.22, which means BEAT is trading at a premium to the group.
Meanwhile, BEAT's PEG ratio is currently 3.78. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services was holding an average PEG ratio of 1.55 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $67.50, marking a +0.42% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.22%. Meanwhile, the Dow gained 0.7%, and the Nasdaq, a tech-heavy index, added 0.08%.
Prior to today's trading, shares of the heart monitoring device maker had gained 28.48% over the past month. This has outpaced the Medical sector's gain of 7.58% and the S&P 500's gain of 9.27% in that time.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. This is expected to be February 28, 2019. On that day, BEAT is projected to report earnings of $0.42 per share, which would represent year-over-year growth of 31.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $103.02 million, up 12.29% from the year-ago period.
Investors might also notice recent changes to analyst estimates for BEAT. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BEAT is currently a Zacks Rank #1 (Strong Buy).
Digging into valuation, BEAT currently has a Forward P/E ratio of 37.76. For comparison, its industry has an average Forward P/E of 20.22, which means BEAT is trading at a premium to the group.
Meanwhile, BEAT's PEG ratio is currently 3.78. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services was holding an average PEG ratio of 1.55 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.